Are medicines that block interleukin‐1 (a protein involved in immune responses) effective treatments for COVID‐19 and do they cause unwanted effects?

<p>Cochrane is producing a growing series of reviews on the care of patients with COVID-19. In January 2022, we published a new review of a group of treatments called interleukin-1 blocking agents and we asked lead author, Mauricia Davidson from Cochrane France, to tell us about the findings.</p>